• 6.7
    2025 CiteScore

Editor-in-Chief

Professor Danny Altmann

 

Associate Editors

Dr Rachael Bashford-Rogers

Dr Daniel Douek

 

Editorial Board

Share your research with Oxford Open Immunology

From fundamental discoveries to clinical advances, we publish immunology research that improves our understanding and treatment of disease. Join a journal championing a bench-to-bedside approach across the full spectrum of immunology.

Learn more about the journal

Latest Articles

The VERX: a transient flare-up of Long COVID symptoms
Thomas Bunker
Oxford Open Immunology, iqag017, https://doi.org/10.1093/oxfimm/iqag017
People with Long COVID frequently experience strong transient flare-ups triggered by various foods, supplements, and medicines. We propose that the increased symptoms, pressure, aches, and pains felt during a flare-up reflect transiently stronger antiviral immune responses at sites of low-level ...
Patients know best: DESTINIES Patient Panel appraisal of a novel, risk-stratified approach to COVID-19 disease surveillance in the adult immunosuppressed
Meredith Leston and others
Oxford Open Immunology, Volume 7, Issue 1, 2026, iqag015, https://doi.org/10.1093/oxfimm/iqag015
The immunosuppressed are poorly represented in disease surveillance and pharmacovigilance dataflows, proving especially consequential during the COVID-19 pandemic. This mixed methods study recruited a panel of immunosuppressed patients (DESTINIES Patient Panel) to quality assure a new digital ...
An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial
Mark A Faghy and others
Oxford Open Immunology, Volume 7, Issue 1, 2026, iqag014, https://doi.org/10.1093/oxfimm/iqag014
Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the ...
Structural homology and binding ability comparisons of epitope pair candidates for molecular mimicry triggering of type 1 diabetes mellitus
Ryan Gardner and others
Oxford Open Immunology, Volume 7, Issue 1, 2026, iqag013, https://doi.org/10.1093/oxfimm/iqag013
Molecular mimicry is the process by which foreign peptides contain epitopes similar to self-peptides, potentially inducing autoimmune responses. Identifying potential molecular mimics and studying their properties is key to understanding the onset of autoimmune diseases such as type 1 diabetes ...
A call to predoctoral researchers: introducing the Robin Weiss Science Writing Prize—celebrating creativity in science
Daniel M Altmann
Oxford Open Immunology, Volume 7, Issue 1, 2026, iqag012, https://doi.org/10.1093/oxfimm/iqag012
What is it that medical journal editors actually do? Those who haven’t been closely involved with the inner workings of academic journals might imagine the role as essentially a gatekeeper, deciding which of the submitted manuscripts may or may not be published. If the journal is operating well ...

Most Read

An open-label feasibility study of remdesivir in long COVID: results from the ERASE LC trial
Mark A Faghy and others
Treatment of acute COVID-19 with anti-viral and immunomodulator medications demonstrates a reduced risk of long-term outcomes. To date, remdesivir, an intravenous (IV) antiviral that prevents RNA transcription, has not been evaluated in people with Long COVID (LC). This study assessed the ...
The current state and future of T-cell exhaustion research
Edward Jenkins and others
‘Exhaustion’ is a term used to describe a state of native and redirected T-cell hypo-responsiveness resulting from persistent antigen exposure during chronic viral infections or cancer. Although a well-established phenotype across mice and humans, exhaustion at the molecular level remains poorly ...
Incidence age is bimodal for myalgic encephalomyelitis/chronic fatigue syndrome, with higher severity burden for early onset disease
Simon J McGrath and others
Myalgic Encephalomyelitis, or Chronic Fatigue Syndrome (ME/CFS), is a disease of uncertain origin. Studies of Norwegian health records have suggested that ME/CFS incidence across age groups is bimodal—a characteristic that could provide insight into the aetiology of the disease. Here, we analysed ...
Vaccine responses in ageing and chronic viral infection
Chloe Rees-Spear and Laura E McCoy
Over the last few decades, changing population demographics have shown that there are a growing number of individuals living past the age of 60. With this expanding older population comes an increase in individuals that are more susceptible to chronic illness and disease. An important part of ...
In-depth characterization of T cell responses with a combined Activation-Induced Marker (AIM) and Intracellular Cytokine Staining (ICS) assay
Yeji Lee and others
Since T cells are key mediators in the adaptive immune system, evaluating antigen-specific T cell immune responses is pivotal to understanding immune function. Commonly used methods for measuring T cell responses include Activation-Induced Marker (AIM) assays and Intracellular Cytokine Staining ...
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Gift article access

Please create a link below to share with others. This will provide temporary access to this restricted article.

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

The link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period